Advertisement

Related Videos

Cody Peer, PhD, on Simulating Alternative Schedules for Checkpoint Inhibitors

Clinical Trial Design: Statistical Options/Challenges Panel Discussion

Kelvin Chan, MD, FRCPC, MSc, PhD, on Opportunities to Optimize Cancer Drug Policies: The Canadian Perspective

Robin Feldman, JD: Are Dubious Patents a Large or Small Issue?

Clifford A. Hudis, MD: Are Cancer Drug Prices in the U.S. the Problem or the Symptom?

Advertisement

Advertisement




Feb
08
Today In Oncology
A Paradigm Shift In Treating Adult AML?
Lymph Node Examination Should be Expanded to Accurately Assess Metastasis in NSCLC, Research Says
VTE During Perioperative Therapy in Resectable and Borderline Resectable Pancreatic Cancer
Agent Orange Exposure Linked With Risk for Acral Melanoma in Veterans
FDA Provides Safety Labeling Update for Capecitabine and Fluorouracil on Risks Associated With DPD Deficiency
View More 
Advertisement
© 2026 HSP News Service, L.L.C.
Conexiant Oncology Logo